Investor Presentaiton slide image

Investor Presentaiton

Investor presentation First three months of 2017 Slide 108 Higher profitability in the biopharmaceuticals segment driven by lower COGS and S&D Diabetes & Obesity P&L - full year 2016 DKK billion 100 Biopharmaceuticals P&L – full year 2016 DKK billion 30 -15% 80 -28% 60 40 20 24 -12% -17% -13% -4% +1% 54% 18 -12% -3% +1% 42% 12 0 Sales COGS S&D R&D Admin ΟΟΙ OP 6 Sales COGS S&D R&D Admin OOI OP P&L: Profit and Loss; COGS: Cost of goods sold; OOI: Other operating income; OP: Operating profit S&D: Sales and distribution cost; R&D: research and development cost; Admin: administrative cost P&L: Profit and Loss; COGS: Cost of goods sold; OOI: Other operating income; OP: Operating profit S&D: Sales and distribution cost; R&D: research and development cost; Admin: administrative cost changing diabetes® novo nordisk
View entire presentation